Technical Analysis for ATXI - Avenue Therapeutics, Inc.

Grade Last Price % Change Price Change
grade C 6.11 0.83% 0.05
ATXI closed up 0.83 percent on Thursday, September 19, 2019, on 1.12 times normal volume. It was able to find support at its 50 day moving average. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Down
See historical ATXI trend table...

Date Alert Name Type % Chg
50 DMA Support Bullish 0.00%
Bullish Engulfing Bullish 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Oversold Stochastic Weakness 0.00%
Crossed Above 50 DMA Bullish 0.83%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.83%
Bollinger Band Squeeze Range Contraction 0.83%
Narrow Range Bar Range Contraction 0.83%
Stochastic Reached Oversold Weakness 0.83%

Older signals for ATXI ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Avenue Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in acquiring, licensing, developing and commercializing products principally for use in the acute or intensive care hospital setting. Its product candidate is intravenous (IV) Tramadol, an intravenous formulation of tramadol hydrochloride (HCl), for the management of moderate to moderately severe postoperative pain. Tramadol, a synthetic dual-acting opioid, is a centrally acting analgesic with weak opioid agonist properties. It also works via the inhibition of serotonin and noradrenaline re-uptake and blocking nociceptive impulses at the spinal level. Tramadol is also combined with acetaminophen (APAP) or nonsteroidal anti-inflammatory drugs (NSAIDS) in clinical practice. During the year ending December 31, 2016, the Company had completed a pharmacokinetics (PK) study for IV Tramadol in healthy volunteers.
Pharmaceutical Drugs Chemical Compounds Analgesics Pharmacokinetics Hepatotoxins Neurochemistry Amines Opioid Paracetamol
Is ATXI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 7.98
52 Week Low 2.08
Average Volume 14,744
200-Day Moving Average 5.5615
50-Day Moving Average 6.0545
20-Day Moving Average 6.177
10-Day Moving Average 6.163
Average True Range 0.175
ADX 14.07
+DI 10.7804
-DI 20.7889
Chandelier Exit (Long, 3 ATRs ) 5.835
Chandelier Exit (Short, 3 ATRs ) 6.375
Upper Bollinger Band 6.3545
Lower Bollinger Band 5.9995
Percent B (%b) 0.31
BandWidth 5.747126
MACD Line 0.0202
MACD Signal Line 0.0429
MACD Histogram -0.0227
Fundamentals Value
Market Cap 61.35 Million
Num Shares 10 Million
EPS -0.44
Price-to-Earnings (P/E) Ratio -13.89
Price-to-Sales 0.00
Price-to-Book 1.57
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.28
Resistance 3 (R3) 6.26 6.18 6.25
Resistance 2 (R2) 6.18 6.14 6.19 6.24
Resistance 1 (R1) 6.15 6.12 6.17 6.17 6.23
Pivot Point 6.07 6.07 6.08 6.08 6.07
Support 1 (S1) 6.04 6.03 6.06 6.06 5.99
Support 2 (S2) 5.96 6.01 5.97 5.98
Support 3 (S3) 5.93 5.96 5.97
Support 4 (S4) 5.95